Miriam E. John - 07 May 2021 Form 4 Insider Report for Leidos Holdings, Inc. (LDOS)

Reporting relationship: Director
Issuer ticker: LDOS
Reported as of: 07 May 2021
Net transaction value: $0
SEC form: 4
Accepted by SEC: 11 May 2021, 19:46:56 UTC
Next SEC filing: 28 May 2021
Source filing: View source filing
Reporting owner signature: /s/ Ramune M. Kligys, Attorney-in-Fact

Key filing fact

Miriam E. John filed Form 4 for Leidos Holdings, Inc. (LDOS) on 11 May 2021.

Key facts

This page summarizes Miriam E. John's Form 4 filing for Leidos Holdings, Inc. (LDOS).
2 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 11 May 2021, 19:46.

Change

No earlier filing in this sequence is available for direct comparison.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

LDOS transaction

Common Stock

Award

Transaction value: $0
Shares: +1,059
Change %: +1.5%
Price: $0.000000
Shares after: 73,998
Date: 07 May 2021
Ownership: By Key Executive Stock Deferral Plan

LDOS holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 20,724
Date: 07 May 2021
Ownership: Direct

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

LDOS transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value: $0
Shares: +2,123
Change %
Price: $0.000000
Shares after: 2,123
Date: 07 May 2021
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 2,123
Exercise price: $103.90
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

The option shall vest and become exercisable in full on the earlier of (i) the first anniversary of the Grant Date, or (ii) the date that the next annual meeting of the stockholders of the Company is concluded.